Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network

Cancer Treatment and Research Communications

Anupama Vasudevan¹  Sarika Ogale²  Yunfei Wang²  Eric Nadler³ 

[1] Corresponding author.;Ontada, 6555 State Highway 161, Irving, TX 75039, United States;The US Oncology Network, 10101 Woodloch Forest Dr, The Woodlands, TX 77380, United States;

关键词: NSCLC;    Testing patterns;    Biomarkers;    Real-world;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: This study investigated biomarker testing and biomarker-guided treatment among patients with metastatic NSCLC in a real-world setting. Methods: This retrospective study examined adult patients diagnosed with de novo mNSCLC between 01-Jan-2016 and 30-Sep-2019, with follow-up through 31-Dec-2019 using The US Oncology Network structured electronic health records data, with chart review for a subset. Results: Of 2257 patients, 76.3% had results for ≥1 driver mutation (DM) or programmed death ligand-1 (PD-L1) during the study observation period. The proportion with results for all 4 DM before 1L initiation increased from 2017 to 2019. Over 40% had results for anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), and c-ros oncogene 1 (ROS1) and 22% for B-Raf proto-oncogene (BRAF) before 1L initiation by structured data. In the chart review subset (n = 197), >70% had results for ALK, EGFR, or ROS1 with 44% for BRAF. Of the 42 ALK+ patients, 5 had results before 1L treatment and 3 received 1L ALK inhibitors. Similar, for the other biomarkers, not all who tested positive for a DM received 1L targeted therapy. The proportion of biomarker-positive patients receiving 1L targeted therapy was higher in chart review versus structured data. However, in both analyses, a substantial proportion did not have results for all 4 DM plus PD-L1 tests for appropriate biomarker-directed 1L treatment selection. Conclusions: Despite increasing biomarker testing rates, reduced turnaround times, and availability of promising biomarker-based therapies, inadequate testing in the community oncology setting means that not all eligible patients are receiving the most effective therapies up front.

【 授权许可】

Unknown